Group 1 - Sichuan Chengyu's wholly-owned subsidiary plans to acquire 85% equity of Hubei Jingyi Company for 2.409 billion yuan, enhancing the company's control over highway projects [1] - Huadian Technology signed contracts worth approximately 815 million yuan with Huadian Technology Group for a wind power hydrogen production project [2] - Dongfang Cable and its subsidiary won projects totaling approximately 3.125 billion yuan, accounting for 34.37% of the company's audited revenue for 2024 [3] Group 2 - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at weight control and metabolic regulation [4] - Qingdao Port plans to invest approximately 15.7 billion yuan in two terminal projects [5] - Jingu Co. received a notification to supply low-carbon wheels for two export models to a major domestic car manufacturer, with production expected in 2026 [6] Group 3 - ST Xingguang won a procurement project worth approximately 22.955 million yuan, accounting for 11.96% of the company's revenue for 2024 [7] - Xinbo Co. plans to jointly invest in an alloy materials research institute with partners, focusing on high-performance materials for various industries [8] - Tianqi Lithium's third-phase lithium concentrate expansion project has been completed and is undergoing trial production, with a total capacity of 2.14 million tons per year [9] Group 4 - Changfei Fiber reported that new fiber optic products related to data centers represent a small proportion of total demand [10] - Dongfang Bio's subsidiaries obtained multiple medical device registration certificates, including various testing kits [11] - Xiugang Co. plans to use up to 500 million yuan of idle fundraising for cash management in safe, liquid investment products [12] Group 5 - Jifeng Co. received a project designation for passenger car seat assemblies from a European luxury brand, with a total lifecycle value of approximately 9.8 billion yuan [13] - CanSino initiated Phase I clinical trials for a combined vaccine, completing the first subject enrollment [14] - Dayu Water-saving's subsidiary pre-won a drainage project worth 140 million yuan and another project worth 1 billion yuan [15] Group 6 - Yutong Pharmaceutical's subsidiary received clinical trial approval for YKYY032 injection for treating hyperlipoproteinemia [17] - Diweier announced the departure of a core technical personnel, impacting its technical leadership [18] - Weilang Co.'s controlling shareholder received regulatory measures from the Shandong Securities Regulatory Bureau for failing to fulfill a commitment [19] Group 7 - Xiehe Electronics invested 5 million yuan in a private equity fund focusing on hard technology sectors [20] - Phoenix Optical received a government subsidy of 4.7053 million yuan, representing 35% of its projected net profit for 2024 [21] - China State Construction reported a 0.9% year-on-year increase in new contracts signed in the first 11 months of 2025, totaling 4.0408 trillion yuan [22] Group 8 - Nanguang Energy's pumped storage power station units 1 and 2 have entered trial operation, with units 3 and 4 expected to follow by year-end [23] - Jindalai plans to invest 280 million yuan to acquire a 34% stake in Yunnan Jici Medical Technology [24] - Geer Software terminated its planned acquisition of a majority stake in Weipin Zhiyuan due to failure to reach agreement on key terms [25] Group 9 - Ningbo Fubang completed the absorption merger of its wholly-owned subsidiary, inheriting all assets and liabilities [26] - Zhongyuan Neipei signed a strategic cooperation framework agreement with Ningbo Puzhi Company for humanoid robot-related business [28] - Gongyuan Co. announced a business integration and relocation of its production lines in the East China region [29] Group 10 - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in a comprehensive utilization project for waste salt [30] - Kain Technology announced the departure of a core technical personnel, impacting its research capabilities [31] - ST Renfu received approval for clinical trials of a new drug for idiopathic pulmonary fibrosis [32] Group 11 - Sanbo Brain Science's established brain science fund has completed registration with the Asset Management Association of China [33] - Tongyou Technology plans to apply for a 70 million yuan credit line from Beijing Bank, using its property as collateral [34] - Bai Ao Intelligent signed a significant equipment sales contract worth approximately 27.5021 million yuan [35] Group 12 - ST Xinyan received all restructuring investment funds totaling 2.239 billion yuan, entering the execution phase of its restructuring plan [36] - Dalu Real Estate's subsidiary decided to terminate a planned acquisition of a 60% stake in Beijing Chengzhu Real Estate [38] - Huiyu Pharmaceutical's products received marketing approval in Italy and Norway [39]

Core Viewpoint - The company announced that core technical personnel, Mr. Wang Tao, will not renew his labor contract upon expiration, and he will no longer hold any position within the company from that date [1] Group 1 - Mr. Wang Tao has signed a confidentiality agreement and a non-compete agreement, which impose corresponding confidentiality and non-compete obligations [1] - The work responsibilities managed by Mr. Wang Tao have been successfully handed over [1] - His departure is not expected to adversely affect the company's daily operations, technological research and development, or production activities, nor will it impact the core technologies owned by the company [1]

Company Overview - Kaiyin Technology (SH 688687) announced on December 19 that core technical personnel, Mr. Wang Tao, will no longer hold any position in the company due to the expiration of his labor contract. The company expressed gratitude for his contributions to its development [1] Financial Performance - For the year 2024, Kaiyin Technology's revenue composition is as follows: pharmaceutical manufacturing accounts for 99.17%, while other businesses make up 0.83% [1] - As of the report date, the market capitalization of Kaiyin Technology is 4.3 billion yuan [1]

证券代码：688687 证券简称：凯因科技 公告编号：2025-037 北京凯因科技股份有限公司 关于公司核心技术人员离职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京凯因科技股份有限公司（以下简称"公司"）核心技术人员汪涛先生 因劳动合同到期，经与公司协商一致不再续签，自其劳动合同到期之日起不再担 任公司任何职务。 汪涛先生与公司签订有《保守商业秘密协议书》及《竞业限制协议》，负 有相应的保密义务和竞业限制义务，其负责的工作已交接完毕，其离职不会对公 司的日常运营、技术研发和生产经营产生不利影响，不会影响公司拥有的核心技 术。 一、核心技术人员离职的具体情况 公司核心技术人员汪涛先生因劳动合同到期，经与公司协商一致不再续签， 并于近日办理完离职手续。离职后，汪涛先生不再担任公司任何职务，公司及董 事会对汪涛先生为公司发展所做出的贡献表示衷心感谢。 （一）核心技术人员的具体情况 （二）参与的研发项目和专利情况 汪涛先生在任职期间参与了公司的研发指导工作，目前已完成工作交接，汪 涛先生的离职不会 ...

Core Viewpoint - The company announced that its core technical personnel, Mr. Wang Tao, will not renew his labor contract upon expiration and will no longer hold any position within the company. This decision was made through mutual agreement between Mr. Wang and the company [1]. Group 1 - Mr. Wang Tao has signed a "Confidentiality Agreement" and a "Non-Compete Agreement," which impose corresponding confidentiality and non-compete obligations on him [1]. - The work responsibilities managed by Mr. Wang have been successfully handed over, ensuring a smooth transition [1]. - His departure is not expected to adversely affect the company's daily operations, technological research and development, or production activities, nor will it impact the core technologies owned by the company [1].

Core Viewpoint - The company announced that its core technical personnel, Mr. Wang Tao, will not renew his labor contract upon expiration and will no longer hold any position within the company. His departure is not expected to negatively impact ongoing projects or the company's operations [1] Group 1 - Mr. Wang Tao participated in the company's research and development guidance during his tenure [1] - The company has completed the work handover process, ensuring a smooth transition [1] - The company asserts that Mr. Wang's departure will not adversely affect its daily operations, technical research, or production activities [1]

证券日报网讯12月11日，凯因科技在互动平台回答投资者提问时表示，截至2025年12月10日，公司股东 人数为12972户。 ...

证券代码：688687 证券简称：凯因科技 公告编号：2025-036 北京凯因科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京凯因科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 24 日 发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 8 日下午 15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2025年第三季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2025 年 12 月 8 日（星期一）下午 15:00-16:00。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 ...

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

证券日报网讯凯因科技11月24日在互动平台回答投资者提问时表示，二级市场股价受多种因素影响，包 括宏观环境、市场变化、投资者偏好和预期等。公司始终高度重视中小股东利益，未来公司会坚持聚焦 主营业务，做好各项生产经营管理工作，完善治理结构，努力为股东带来稳定、长期的价值回报。 （文章来源：证券日报） ...